Bing

SEARCH HISTORY

Small cap orphan drug stocks Zalicus Inc (NASDAQ: ZLCS), Omeros Corporation (NASDAQ ... The designation will also qualify companies for benefits across all stages of drug development, such as accelerated approval processes, seven years of market ...
Smallcap Network · ByJohn Udovich · 10/1/2013
Zalicus (NASDAQ: ZLCS) is my top pick for an unknown biotech winner in 2011 ... once the distributors have their initial stock, sales fall off for a quarter or two as the sell-through builds. That is what happened in the September quarter, when Zalicus ...
Investor Place · 12/27/2010
NEW YORK (TheStreet) -- Zalicus (ZLCS) surged Thursday after Epirus Switzerland announced clinical data from a Phase 3 study of BOW015, a biosimilar infliximab, in patients with active rheumatoid arthritis. The study is as an equivalence trial to compare ...
The Street · 12/6/2014
More from Bing News
They are listed in descending order of the largest price declines from 52-week highs. (click to enlarge) Zalicus (ZLCS) stock price was pushed off a cliff when its phase 2 trial of Z160 for chronic pain did not meet endpoints. ZLCS now has a tiny market ...
Seeking Alpha · 3/24/2014
Answers to frequently asked questions from stockholders regarding the reverse stock split can be found at www.zalicus.com in the Investors and Media Overview section. About Zalicus Zalicus Inc. (Nasdaq Capital Market: ZLCS) is a biopharmaceutical …
The Motley Fool · 10/2/2013
Zalicus Inc. ZLCS is currently up (+179.07%) from its recent 52-week low, which has prompted Growing Stock Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll. GrowingStockReport.com monitors and scans the markets …
Market Watch · 10/1/2013
Zalicus Inc. (NASDAQ: ZLCS) 50% HIGHER; stock gained after-hours on Wednesday. Traders discussed Phase 3 data from Epirus BOW015 for treatment of rheumatoid arthritis. (Note: On April 16th, Zalicus Inc. and Epirus Biopharmaceuticals announced …
StreetInsider · 6/12/2014
New York, NY - (ACCESSWIRE) - 11/11/2013 - Growing Stock Report initiates its NASDAQ Active Stock Weekly Watch List adding Zalicus Inc. (NASDAQ:ZLCS - News), CollabRx, Inc. (NASDAQ:CLRX - News), Discovery Laboratories Inc. (NASDAQ …
Finance Yahoo · 11/11/2013
President and CEO Mark Corrigan sold 112,850 shares of ZLCS stock on 01/15/2013 at the average price of $0.77. Mark Corrigan owns at least 844,090 shares after this. EverBank Financial Corp. (EVER): Chairman and CEO Robert M. Clements sold 110 …
Guru Focus · 1/22/2013
ZLCS) today announced that it has filed a Certificate of Amendment to its Sixth Amended and Restated Certificate of Incorporation, with the Secretary of State of the State of Delaware to effect a 1-for-6 reverse stock split of Zalicus common stock ...
Reuters · 10/3/2013